IFITM3-specific antibody reveals IFN preferences and slow IFN induction of the antiviral factor IFITM3 in humans.

A549 Cells Antiviral Agents / metabolism CD4-Positive T-Lymphocytes / metabolism Cell Line Cell Line, Tumor HEK293 Cells Humans Interferon Type I / metabolism Lymphocytes / metabolism Membrane Proteins / metabolism RNA-Binding Proteins / metabolism
IFITM3 IFN innate immunity myeloid cells viral restriction

Journal

European journal of immunology
ISSN: 1521-4141
Titre abrégé: Eur J Immunol
Pays: Germany
ID NLM: 1273201

Informations de publication

Date de publication:
03 2021
Historique:
received: 23 04 2020
revised: 01 10 2020
accepted: 22 10 2020
pubmed: 31 10 2020
medline: 21 8 2021
entrez: 30 10 2020
Statut: ppublish

Résumé

Using a specific antibody, we found that expression of the viral restriction factor IFITM3 differs across cell types within the immune compartment with higher expression in myeloid rather than lymphoid cells. IFITM3 expression was increased following IFN stimulation, mostly type I, in immune cells, with the exception of T cells.

Identifiants

DOI: 10.1002/eji.202048706 PMID: 33125710 PMC: PMC7983929
pubmed: 33125710
doi: 10.1002/eji.202048706
pmc: PMC7983929
doi:

Substances chimiques

Antiviral Agents 0
IFITM3 protein, human 0
Interferon Type I 0
Membrane Proteins 0
RNA-Binding Proteins 0

Types de publication

Letter Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

742-745

Subventions

Organisme : Wellcome Trust
ID : 207503/Z/17/Z
Pays : United Kingdom
Organisme : Medical Research Council
ID : G1000800
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/L018942/1
Pays : United Kingdom

Informations de copyright

© 2020 The Authors. European Journal of Immunology published by Wiley-VCH GmbH.

Références

Cell. 2018 Jan 25;172(3):423-438.e25
pubmed: 29249360
Trends Microbiol. 2010 Sep;18(9):388-96
pubmed: 20688520
Oncogene. 2000 May 15;19(21):2619-27
pubmed: 10851061
Cell. 2009 Dec 24;139(7):1243-54
pubmed: 20064371
J Interferon Cytokine Res. 2016 Dec;36(12):671-680
pubmed: 27617757
PLoS Pathog. 2012 Sep;8(9):e1002909
pubmed: 22969429
Immunology. 2020 Apr;159(4):365-372
pubmed: 31792954
PLoS Pathog. 2011 Jan 06;7(1):e1001258
pubmed: 21253575

Auteurs

Dannielle Wellington (D)

MRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, Oxford University, Oxford, UK.
Nuffield Department of Medicine, Chinese Academy of Medical Sciences (CAMS) Oxford Institute, Oxford University, Oxford, UK.
ORCID: 0000-0002-9277-0306

Zixi Yin (Z)

MRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, Oxford University, Oxford, UK.
Nuffield Department of Medicine, Chinese Academy of Medical Sciences (CAMS) Oxford Institute, Oxford University, Oxford, UK.

Adi Abdel-Haq (A)

MRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, Oxford University, Oxford, UK.
Charles Tanford-Proteinzentrum, Martin-Luther-Universität Halle-Wittenberg, Institut für Molekulare Medizin, Kurt-Mothes-Straße 3a, Halle, Germany.

Liwei Zhang (L)

MRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, Oxford University, Oxford, UK.

Jessica Forbester (J)

MRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, Oxford University, Oxford, UK.
Division of Infection and Immunity/Systems Immunity University Research Institute, Cardiff University, Cardiff, UK.

Kerry Kite (K)

MRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, Oxford University, Oxford, UK.

Ushani Rajapaksa (U)

MRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, Oxford University, Oxford, UK.

Henry Laurenson-Schafer (H)

MRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, Oxford University, Oxford, UK.

Shokouh Makvandi-Nejad (S)

MRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, Oxford University, Oxford, UK.

Boquan Jin (B)

Fourth Military Medical University, Xian, China.

Emma Bowes (E)

Oxford Radcliffe Biobank, Nuffield Department of Surgical Sciences, Oxford University, Oxford, UK.

Krishnageetha Manoharan (K)

Oxford Radcliffe Biobank, Nuffield Department of Surgical Sciences, Oxford University, Oxford, UK.

David Maldonado-Perez (D)

Oxford Radcliffe Biobank, Nuffield Department of Surgical Sciences, Oxford University, Oxford, UK.

Clare Verrill (C)

Oxford Radcliffe Biobank, Nuffield Department of Surgical Sciences, Oxford University, Oxford, UK.

Ian R Humphreys (IR)

Division of Infection and Immunity/Systems Immunity University Research Institute, Cardiff University, Cardiff, UK.

Tao Dong (T)

MRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, Oxford University, Oxford, UK.
Nuffield Department of Medicine, Chinese Academy of Medical Sciences (CAMS) Oxford Institute, Oxford University, Oxford, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Cellules › Cellules épithéliales › Cellules A549 › IFITM3-specific antibody reveals IFN...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Anti-infectieux › Antiviraux › IFITM3-specific antibody reveals IFN...
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Leucocytes › Agranulocytes › Lymphocytes › Lymphocytes T › Lymphocytes T CD4+ › IFITM3-specific antibody reveals IFN...
questionsmedicales.fr › Cellules › Cellules cultivées › Lignée cellulaire › IFITM3-specific antibody reveals IFN...
questionsmedicales.fr › Cellules › Cellules cultivées › Cellules cancéreuses en culture › Lignée cellulaire tumorale › IFITM3-specific antibody reveals IFN...
questionsmedicales.fr › Cellules › Cellules épithéliales › Cellules HEK293 › IFITM3-specific antibody reveals IFN...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › IFITM3-specific antibody reveals IFN...
questionsmedicales.fr › Facteurs biologiques › Protéines et peptides de signalisation intercellulaire › Cytokines › Interférons › Interféron de type I › IFITM3-specific antibody reveals IFN...
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Leucocytes › Agranulocytes › Lymphocytes › IFITM3-specific antibody reveals IFN...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › IFITM3-specific antibody reveals IFN...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Nucléoprotéines › Protéines de liaison à l'ARN › IFITM3-specific antibody reveals IFN...